Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 10761 - 10768 of 12007 results

Unsealed Qui Tams Show That Government Declination is Not Always the End

December 5, 2013| Blog| Viewpoint

Covenant, Shmovenant? Ten-Year Nationwide Non-Compete in Asset Purchase Agreement Forms the Basis for Tortious Interference With Contract Claim

December 4, 2013| Blog| Viewpoint

The “Relocation Costs” Reimbursement Arrangement: A Section 409A Trap for the Unwary.

December 4, 2013| Blog| Viewpoint

Time to Change that Facebook Password

December 4, 2013| Blog| Viewpoint

FCC Clarifies Rule Governing Foreign Ownership of Broadcast Stations

December 4, 2013| Advisory| Viewpoint

New York Federal District Court Endorses Use of Fluctuating Workweek Overtime Payment Method Where Employer Pays Performance-Based Bonuses to Non-Exempt Salaried Employees

December 3, 2013| Blog| Viewpoint

CMS Issues Medicare Physician Fee Schedule Without Finalizing Proposal Most Harmful to Independent Laboratories

December 3, 2013| Blog| Viewpoint

The Dark Cloud Over Nordstrom’s Black Friday: California Law May Prohibit Retailers from Collecting Email Addresses at Checkout

December 3, 2013| Blog| Viewpoint

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases